Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00092235

Recruitment Status : Recruiting

First Posted : September 22, 2004

Last Update Posted : January 15, 2021

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Study Description

Brief Summary:

Background:

Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival.
Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North America and about 50% of patients who are transplanted develop cGVHD.
Chronic GVHD is also a disorder that simultaneously affects many organ systems in highly variable fashion and requires complex and coordinated medical management by multiple medical specialties. There is an urgent need for progress in understanding and effective treatments for cGVHD as it is one of the most serious complications of cancer therapy and hematopoietic stem cell transplantation.

Objectives:

To establish a multidisciplinary clinic infrastructure for study of the pathogenesis and natural history of cGVHD.
To prospectively identify clinical and biological prognostic markers in patients with cGVHD
To develop clinically relevant cGVHD grading scales
To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation
To identify potential clinical and biological markers of cGVHD activity
To improve understanding of the biology of cGVHD-associated graft-versus-tumor effects
To identify potential patients for cGVHD treatment protocols at the NCI and NIH

Eligibility:

-Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis.

Design:

Patient undergoes initial clinical and laboratory multispecialty work-up at the NCI cGVHD clinic.
Minimally invasive biopsies and rarely, deep tissue biopsy may be obtained to confirm the diagnosis and/or rule-out other pathologic process (in adults only).
Long tem data collection for evaluation of long-term outcomes will be conducted anually as feasible

Condition or disease
Chronic Graft vs Host Disease

Detailed Description:

Background:

Chronic graft-versus-host disease (cGVHD) is a multi-organ alloimmune and autoimmune disorder that occurs following allogeneic hematopoietic stem cell transplantation (alloHSCT). It is characterized by immune dysregulation, immunodeficiency, impaired organ function, and decreased survival.
Each year about 8000 patients receive allogeneic hematopoietic stem cell transplant (alloHSCT) in North America and about 50% of patients who are transplanted develop cGVHD.
Chronic GVHD is also a disorder that simultaneously affects many organ systems in highly variable fashion and requires complex and coordinated medical management by multiple medical specialties. There is an urgent need for progress in understanding and effective treatments for cGVHD as it is one of the most serious complications of cancer therapy and hematopoietic stem cell transplantation.

Objectives:

To establish a multidisciplinary clinic infrastructure for study of the pathogenesis and natural history of cGVHD.
To prospectively identify clinical and biological prognostic markers in patients with cGVHD
To develop clinically relevant cGVHD grading scales
To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation
To identify potential clinical and biological markers of cGVHD activity
To improve understanding of the biology of cGVHD-associated graft-versus-tumor effects
To identify potential patients for cGVHD treatment protocols at the NCI and NIH

Eligibility:

-Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis.

Design:

Patient undergoes initial clinical and laboratory multispecialty work-up at the NCI cGVHD clinic.
Minimally invasive biopsies and rarely, deep tissue biopsy may be obtained to confirm the diagnosis and/or rule-out other pathologic process (in adults only).
Long tem data collection for evaluation of long-term outcomes will be conducted anually as feasible

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	650 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease
Actual Study Start Date :	October 26, 2004

Resource links provided by the National Library of Medicine

Genetic and Rare Diseases Information Center resources: Homologous Wasting Disease Chronic Graft Versus Host Disease

U.S. FDA Resources

Groups and Cohorts

Group/Cohort
Cohort 1 Patients who have undergone an allogeneic stem cell transplant and are diagnosed withcGVHD
Cohort 2 Pediatric patients who have undergone an allogeneic stem cell transplant and arediagnosed with cGVHD
Cohort 3 Patients who have undergone an allogeneic stem cell transplant and choose to submitbiopsy, blood and urine samples only
Cohort 4 Patients who have undergone an allogeneic stem cell transplant and are not diagnosed withcGVHD

Outcome Measures

Primary Outcome Measures :

To establish a multidisciplinary clinic infrastructure for study of pathogenesis and natural history of cGVHD [ Time Frame: Ongoing ]
Assessment of clinical and biological characteristics of cGVHD.
To prospectively identify candidate markers for clinical and biological prognostic factors in patients with cGVHD and develop a prognostic model [ Time Frame: 2 years + 3 months after protocol entry ]
Patient evaluations resulting in collection of data via several medical specialties; data will be examined individually and against clinical outcomes
To develop clinically relevant cGVHD grading scales [ Time Frame: Ongoing ]
Develop appropriate staging as a tool for measuring responses or outcomes in clinical studies through prospective collection andanalysis of data.
To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation [ Time Frame: Ongoing ]
Through collection of data via several medical specialties, assess the weight of specific clinical and biological characteristics and diseaseseverity scales for predicting major clinical outcomes.
To identify potential clinical and biological markers of cGVHD activity [ Time Frame: Ongoing ]
Assessment of risk and outcome as related to molecular markers ofpathogenesis and/or stage of disease.
To improve our current understanding of the biology of cGVHD associated graft-versus-tumor effects (GVT). [ Time Frame: Ongoing ]
Studying mechanisms of how cGVHD exerts its anti-cancereffects via laboratory analysis.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	1 Year and older (Child, Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients will be selected via referrals or from patients who were on companion clinical protocols at the NIH.

Criteria

INCLUSION CRITERIA:
1. Any patient age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independently of age or underlying diagnosis
2. Patient or the patient's legal representative is able and willing to provide consent.

EXCLUSION CRITERIA:

Significant medical condition or any other significant circumstance that could in the PIs assessment affect the patient's ability to tolerate, comply, or complete the study
Patients who in the PIs assessment have a life expectancy less than 3 months.

Note: Because it is not always possible to make a clear clinical distinction between acute and chronic GVHD, patients with acute GVHD are not a-priori excluded until the possibility of chronic GVHD is reliably excluded on the basis of the clinical assessments in the cGVHD clinic.
Pregnant women are excluded from this study because multiple tests would need to be excluded for safety of the patient and the fetus.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00092235

Contacts

Layout table for location contacts

Contact: Steven Z Pavletic, M.D.	(240) 760-6174	sp326h@nih.gov

Locations

Layout table for location information

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike	Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators

Layout table for investigator information

Principal Investigator:	Steven Z Pavletic, M.D.	National Cancer Institute (NCI)

More Information

Additional Information:

NIH Clinical Center Detailed Web Page This link exits the ClinicalTrials.gov site

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Katić M, Pirsl F, Steinberg SM, Dobbin M, Curtis LM, Pulanić D, Desnica L, Titarenko I, Pavletic SZ. Vitamin D levels and their associations with survival and major disease outcomes in a large cohort of patients with chronic graft-vs-host disease. Croat Med J. 2016 Jun 30;57(3):276-86.

Curtis LM, Datiles MB 3rd, Steinberg SM, Mitchell SA, Bishop RJ, Cowen EW, Mays J, McCarty JM, Kuzmina Z, Pirsl F, Fowler DH, Gress RE, Pavletic SZ. Predictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice. Haematologica. 2015 Sep;100(9):1228-36. doi: 10.3324/haematol.2015.124131. Epub 2015 Jun 18.

Bassim CW, Fassil H, Dobbin M, Steinberg SM, Baird K, Cole K, Joe G, Comis LE, Mitchell SA, Grkovic L, Edwards D, Mays JW, Cowen EW, Pulanic D, Williams KM, Gress RE, Pavletic SZ. Malnutrition in patients with chronic GVHD. Bone Marrow Transplant. 2014 Oct;49(10):1300-6. doi: 10.1038/bmt.2014.145. Epub 2014 Jul 14.

Martires KJ, Baird K, Steinberg SM, Grkovic L, Joe GO, Williams KM, Mitchell SA, Datiles M, Hakim FT, Pavletic SZ, Cowen EW. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood. 2011 Oct 13;118(15):4250-7. doi: 10.1182/blood-2011-04-350249. Epub 2011 Jul 26.

Clark J, Yao L, Pavletic SZ, Krumlauf M, Mitchell S, Turner ML, Cowen EW. Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease. Arch Dermatol. 2009 Aug;145(8):918-22. doi: 10.1001/archdermatol.2009.78.

Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood. 2009 Apr 9;113(15):3620-30. doi: 10.1182/blood-2008-07-168351. Epub 2009 Jan 23.

Layout table for additonal information

Responsible Party:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00092235
Obsolete Identifiers:	NCT00331968
Other Study ID Numbers:	040281 04-C-0281
First Posted:	September 22, 2004 Key Record Dates
Last Update Posted:	January 15, 2021
Last Verified:	October 6, 2020

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):


cGVHD-associated graft-versus-tumor effects (GVT) Allo-HSCT controls Leukapheresis

Additional relevant MeSH terms:

Layout table for MeSH terms

Graft vs Host Disease Immune System Diseases

To Top